Is Selank known to bind neuropilin-1?

No. Tuftsin's receptor is identified; Selank has no identified receptor, and whether the extension preserves engagement is not established.

Could the extension block binding?

Possibly. It adds three residues to a four-residue peptide at the C-terminus, which could obstruct a pocket engaging the terminal arginine.

Why does this matter?

If Selank does not engage that receptor, its activities cannot be inherited from tuftsin's mechanism and the parent-analogue relationship is weaker than the naming implies.

Selank (Tuftsin Analogue)

The Question the Fragment Literature Does Not Answer

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

Selank is tuftsin with Pro-Gly-Pro appended. Tuftsin signals through neuropilin-1; Selank has no identified receptor. Whether the extension preserves, weakens or blocks engagement with that receptor is not established, and it is the most direct mechanistic question about this compound.

Key facts

Selank: Thr-Lys-Pro-Arg-Pro-Gly-Pro, 7 residues
Tuftsin: Thr-Lys-Pro-Arg, 4 residues, 500.6 Da
Difference: C-terminal Pro-Gly-Pro extension
Tuftsin receptor: Neuropilin-1
Selank receptor: Not identified
Status of the question: Unresolved

Why this is the obvious question

An analogue that consists of an active parent plus an addition raises one question before any other: does the addition interfere with what the parent did? For most fragment or extension compounds this is asked directly. Here the parent's receptor was identified in 2013 and the analogue's mechanism continues to be described in terms of downstream effects rather than receptor engagement.

Why an extension can matter more than it looks

Tuftsin is four residues. Adding three more increases its length by 75%, and the addition sits at the C-terminus. Whether a receptor tolerates that depends entirely on how it engages the ligand — if the C-terminal arginine sits in a binding pocket, appending residues to it could obstruct the interaction completely.

Research material referenced

Selank 10mg — third-party HPLC tested

View — £24.99

The argument that it might not matter

Pro-Gly-Pro was chosen as a stability motif rather than a pharmacophore, and proline-rich extensions are often relatively inert structurally. If the receptor engages the N-terminal end, a C-terminal addition might be tolerated. That is plausible, and plausible is not the same as demonstrated.

What the alternative would imply

If Selank does not engage neuropilin-1, then its reported activities cannot be inherited from tuftsin's mechanism and must arise some other way — which would make the parent-analogue relationship far weaker than the naming implies. Describing Selank as a tuftsin analogue would remain structurally accurate and become pharmacologically misleading.

Why the site's other fragments face the same test

This is the recurring question across the catalogue. TB-500 and thymosin beta-4. Modified GRF and GHRH. KPV and alpha-MSH. Semax and ACTH. In each case the compound is described by reference to a parent, and in each case what actually transfers is a separate empirical question from what the sequence shares.

What can be said honestly

That Selank contains tuftsin's sequence, that tuftsin has an identified receptor and Selank does not, and that no published work establishes whether the analogue engages it. Nothing supplied here holds a marketing authorisation, and no claim is made about any effect in any person.

Quick reference

	Tuftsin	Selank
Sequence	Thr-Lys-Pro-Arg	Thr-Lys-Pro-Arg-Pro-Gly-Pro
Length	4 residues	7 residues
Identified receptor	Neuropilin-1	None
Literature size	~690 records	Substantially smaller

Extended research context

The Selank (Tuftsin Analogue) deep dive

Deep dive: preserving a signal rather than supplying one

Selank's most specifically characterised activity is not receptor binding. Work published in the Bulletin of Experimental Biology and Medicine in 2001 and 2002 reported that it inhibits enkephalin-degrading enzymes, measured directly on plasma enkephalinase activity, thereby extending the half-life of endogenous enkephalins rather than acting at opioid receptors itself. That distinction is routinely muddled and it matters: an agonist activates the receptor wherever the drug reaches, at whatever concentration is given, while a degradation inhibitor only lets the ligand the body is already releasing persist longer. The effect is bounded by endogenous release and occurs only where that release happens. The same logic underlies DPP-4 inhibitors in the incretin field, which prolong native GLP-1 rather than supplying an analogue - and instructively, that class produces much smaller effects than the receptor agonists do.

Deep dive: what the sequence does and does not contain

TKPRPGP is unusual among research peptides for what is absent from it. There is no cysteine, so no disulfide bonds form or scramble and no reducing agent is needed. There is no methionine, so the thioether oxidation that adds 16 Da and dominates handling guidance for MOTS-c and Semax does not apply. There is no asparagine or glutamine either, ruling out deamidation. What remains is straightforward hydrolysis, and three prolines in seven residues resist even enzymatic cleavage well, because proline locks the backbone rotation peptidases require. One practical cost of that composition: no aromatic residues means almost no absorbance at 280 nm, so the standard spectrophotometric quantification method does not work on it.

Deep dive: reading a two-literature evidence base

PubMed indexes roughly 135 Selank records against about 690 for its parent peptide tuftsin - an inversion worth noticing, since most designed analogues eventually outgrow the parent they replaced. Most of the tuftsin literature is immunological and predates Selank entirely, so it is not evidence about Selank. Within Selank's own record the split is the same one Semax shows: mechanistic work in internationally indexed journals, assessable directly; clinical work concentrated in Russian-language publications, indexed by translated title and often without accessible English full text. That is evidence which is hard to verify independently, which is not the same as evidence that is absent, and not the same as evidence that is established.

Research applications

▸Enkephalin and enkephalinase pathway research
▸GABAergic receptor expression studies in rodent models
▸BDNF expression research, including intranasal administration routes
▸Comparative work on proline-stabilised peptide design
▸Tuftsin and immunopeptide structure-activity research

Handling checklist

✓Store lyophilised material cold, dry and protected from light
✓No reducing agent needed — the sequence contains no cysteine
✓No methionine oxidation to expect; a +16 Da satellite warrants explanation
✓Do not rely on 280 nm absorbance — there are no aromatic residues
✓Introduce diluent gently against the vial wall; swirl rather than shake
✓Aliquot to avoid repeated freeze-thaw cycles

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Describing Selank as an opioid or opioid agonist

Fix: Reported work describes inhibition of enkephalin-degrading enzymes, not receptor binding. It preserves endogenous enkephalins rather than supplying an agonist.

✗ Treating the benzodiazepine contrast as a safety claim

Fix: The mechanistic difference is real — expression-level rather than direct allosteric modulation — but it supports no comparative claim about safety or dependence.

✗ Citing tuftsin literature as evidence about Selank

Fix: Tuftsin has roughly five times more papers, most of them immunological and predating Selank. They are different compounds.

✗ Reading a BDNF expression change as a demonstrated outcome

Fix: The work measured expression in rat hippocampus. Expression is upstream of function and upstream again of any clinical claim.

✗ Treating Russian registration as equivalent to MHRA approval

Fix: Authorisations are jurisdictional and do not transfer. Selank has never been assessed by the MHRA, EMA or FDA.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

Is Selank known to bind neuropilin-1?: No. Tuftsin's receptor is identified; Selank has no identified receptor, and whether the extension preserves engagement is not established.
Could the extension block binding?: Possibly. It adds three residues to a four-residue peptide at the C-terminus, which could obstruct a pocket engaging the terminal arginine.
Why does this matter?: If Selank does not engage that receptor, its activities cannot be inherited from tuftsin's mechanism and the parent-analogue relationship is weaker than the naming implies.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Selank (Tuftsin Analogue) articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum